PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (WEIGHT LOSS)
DRUG NAME: CAGRILINTIDE

  • FDA Safety Data Sheet not available (experimental peptide).

  • Frias JP. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023 [PubMed Link]

  • D'Ascanio AM. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2024 [PubMed Link]

  • Lau DC. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021 [PubMed Link]

  • Enebo LB. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021 [PubMed Link]

  • Garvey WT. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025 [PubMed Link]

  • Kruse T. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 [PubMed Link]

  • Davies MJ. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025 [PubMed Link]

  • Dutta D. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2024 [PubMed Link]

  • Becerril S. Cagrilintide plus semaglutide for obesity management. Lancet. 2021 [PubMed Link]

  • Ryan DH. Drugs for Treating Obesity. Handb Exp Pharmacol. 2022 [PubMed Link]

  • Bailey CJ. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023 [PubMed Link]

  • Gogineni P. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Expert Opin Pharmacother. 2024 [PubMed Link]

  • Sidrak WR. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. Indian J Endocrinol Metab. 2024 [PubMed Link]

  • Abdalla Ahmed MA. Advancements in the management of obesity: a review of current evidence and emerging therapies. Expert Rev Endocrinol Metab. 2024 [PubMed Link]

  • Rosenthal A. The role of bioidentical hormone replacement therapy in anti-aging medicine: a review of the literature. Int J Dermatol. 2020 [PubMed Link]

  • Ingram CF, Payne KS, Messore M, Scovell JM. Testosterone therapy and other treatment modalities for female sexual dysfunction. Curr Opin Urol. 2020 [PubMed Link]

  • Martínez-García A, Davis SR. Testosterone use in postmenopausal women. Climacteric. 2021 [PubMed Link]